8-K filed Jun 3, 2026 at 08:03 ET
BioLife Solutions filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference. The presentation highlights FY2025 revenue of $96M (29% organic growth), 26% adjusted EBITDA margin, and provides 17-20% revenue growth guidance for FY2026, with expectations of positive GAAP net income for the full year. The filing is a routine investor relations update with no new material financial disclosures beyond previously reported figures.